Takeda Rare Disorders Digest

We head to the clinic this week to hear about Prof. Joe Sasadeusz's clinical experiences with treating CMV, and the common challenges faced when managing patients with CMV infections. Learn about considerations when selecting between prophylactic and preemptive therapy for patients with CMV infections.See omnystudio.com/listener for privacy information.

We chat with Prof. Joe Sasadeusz about current and upcoming approaches to diagnose and treat CMV infections. Prof. Sasadeusz also shares his thoughts on the strengths and limitations of current prophylactic and preemptive treatment strategies and gives us a glimpse into the future of CMV treatment.See omnystudio.com/listener for privacy information.

CMV is a common and yet permanent infection that poses risks to people with weakened immune systems. In this episode, Prof. Joe Sasadeusz sets the scene by giving an overview of these infections alongside patient advocate, Ms Lisa Foster. CMV infections have serious consequences, especially those in high-risk groups, such as those with AIDS, and patients who are receiving immunosuppressants following a solid organ (SOT) or hematopoietic stem cell transplant (HSCT).See omnystudio.com/listener for privacy information.

In the last episode of this series on DS and LGS, Prof. Rima Nabbout shares details on several clinical cases involving DS and LGS and outlines her thought process when addressing some of the challenges associated with the diagnosis and management of these conditions in real-world settings.See omnystudio.com/listener for privacy information.

In this episode, Prof. Rima Nabbout describes the clinical presentation, and diagnosis of LGS. She also walks us through some of the available treatment modalities and the limitations associated with treating patients with this disease.See omnystudio.com/listener for privacy information.

Prof. Rima Nabbout deep dives into the aetiology of DS, including genetic alterations such as SCN1A mutations. She also tells us about diagnosing and treating these conditions, in addition to some of the challenges she encounters in clinical practice.See omnystudio.com/listener for privacy information.

Prof. Rima Nabbout and patient advocate, Ms Lisa Foster, tell us more about DS and LGS, rare epileptic disorders that are associated with high morbidity and mortality, and the significant impact they have on patients and their families.See omnystudio.com/listener for privacy information.

In the last episode of this series on TTP, Dr Eng Soo Yap shares some of his clinical experiences with the diagnosis and management of immune-mediated and congenital forms of TTP.See omnystudio.com/listener for privacy information.

Dr Eng Soo Yap helps us understand more about the role of therapeutic plasma exchange (TPE) in treating iTTP and cTTP, and some of the challenges associated with the current treatment paradigm. He also shares insights on promising therapeutics such as TAK-755 that are currently under investigation. See omnystudio.com/listener for privacy information.

Despite extensive research in this area, TTP diagnosis continues to be a challenging affair for clinicians. Dr Eng Soo Yap helps us understand more about the current approach to diagnosis, the importance of ADAMTS13 testing, and the challenges associated with distinguishing between iTTP and cTTP. See omnystudio.com/listener for privacy information.

TTP is a life-threatening rare blood disorder requiring rapid diagnosis and treatment. Dr Eng Soo Yap and patient advocate, Ms Lisa Foster, help us understand more about the two main types of TTP, immune-mediated TTP (iTTP) and congenital TTP (cTTP), and the overall impact it has on the patient.See omnystudio.com/listener for privacy information.